Study identifies biomarker linked to poor outcomes in pregnant lupus patients

October 28, 2013

Researchers at Hospital for Special Surgery in New York City have identified a biomarker that may predict poor pregnancy outcomes in lupus patients.

The study, titled "Angiogenic Factor Dysregulation and Risk of Adverse Pregnancy Outcome In Lupus Pregnancies" will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting on October 27 in San Diego.

Investigators found that an imbalance of angiogenic factors, proteins required for the development of the placenta and the health of blood vessels, is associated with poor outcomes. Increased levels of an anti-angiogenic protein called sFlt1 in pregnant patients placed them at increased risk of placental insufficiency and , a potentially life-threatening complication. Scientists determined that higher levels of sFlt1 reduce the activity of other angiogenic proteins (placental growth factor, PIGF; vascular endothelial growth factor, VEGF) that are necessary for growth of the placenta and the mother's blood vessels.

"Pregnant women with lupus or antiphospholipid syndrome are at increased risk for adverse outcomes, particularly preeclampsia, yet identification of those destined for complications has been elusive," said Jane Salmon, MD, director of the Lupus and APS Center of Excellence at Hospital for Special Surgery and lead author of the study. "We prospectively studied patients to see if we could find a biomarker early in pregnancy that would predict a poor outcome."

The study is part of an ongoing, multi-center research initiative led by Dr. Salmon known as PROMISSE (Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic lupus Erythematosus) funded by the National Institutes of Health to identify factors that predict pregnancy complications in women with lupus and antiphospholipid syndrome.

Lupus is a chronic inflammatory disease in which the body's own immune system attacks tissues of the body and can cause complications during pregnancy. Preeclampsia, which is characterized by the onset of high blood pressure and impaired kidney function, is life-threatening to both mother and baby.

Scientists enrolled 384 with lupus and 153 healthy pregnant controls.

Subjects were evaluated and blood was drawn monthly beginning 12 weeks into their pregnancy. Poor pregnancy outcomes were defined as preeclampsia, fetal death, neonatal death, preterm delivery before 36 weeks because of placental insufficiency, or intrauterine growth restriction (IUGR), which refers to a poor growth rate of the baby while in the womb. Levels of sFlt1 and other angiogenic proteins were measured and compared in women with lupus versus controls.

In the study, 20 percent of pregnant developed preeclampsia or another poor outcome. Levels of sFlt1 protein, an anti-angiogenic factor, were significantly higher in patients destined for complications compared to lupus patients whose pregnancies were uncomplicated. In contrast, levels of PlGF, an angiogenic factor, were lower. Alteration in the balance of angiogenic factors was evident as early as 12 to 15 weeks into the pregnancy and persisted throughout pregnancy in women who experienced preeclampsia or another complication.

"Measurement of sFlt1 and PlGF provide a powerful tool to identify pregnant lupus patients at high risk for poor sufficiently early to intervene," Dr. Salmon said. "Hopefully, this will facilitate trials of novel treatments to prevent these devastating complications."

Explore further: Most women with lupus can have successful pregnancy outcomes

More information: ww2.rheumatology.org/apps/MyAn … eting/Abstract/36090

Related Stories

Most women with lupus can have successful pregnancy outcomes

November 6, 2011
Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.

Study sheds light on pregnancy complications and overturns common belief

July 3, 2012
A study led by Hospital for Special Surgery researchers has demonstrated that women who have a specific type of antibody that interferes with blood vessel function are at risk for adverse pregnancy outcomes and that other ...

Young, black women at highest risk for lupus, suffer more life-threatening complications

October 24, 2013
Young, black women have the highest rate of developing lupus and are most likely to be diagnosed at a younger age than whites and during childbearing years, according to a new University of Michigan study of lupus in Southeastern ...

Baby knows best: Fetuses emit hormone crucial to preventing preeclampsia

May 1, 2013
In a study using mice, researchers from the University of North Carolina at Chapel Hill found that a hormone, adrenomedullin, plays a crucial role in preventing the pregnancy complication preeclampsia. Surprisingly, this ...

Recommended for you

Study shows prevalence of knee osteoarthritis has doubled since World War II

August 14, 2017
The average American today is twice as likely to be diagnosed with knee osteoarthritis than in the years before World War II, Harvard scientists say, but that increase can't be blamed on the reasons most might think.

Researchers find arthritis drug could treat blood cancer patients

August 3, 2017
Blood cancer sufferers could be treated with a simple arthritis drug, scientists at the University of Sheffield have discovered.

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.